Corporate Events

Kaken Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended June 30, 2025. For the first quarter, the company reported sales was JPY 18,867 million compared to JPY 18,254 million a year ago. Net income was JPY 271 million compared to JPY 1,754 million a year ago. Basic earnings per share from continuing operations was JPY 7.13 compared to JPY 46.32 a year ago.

Kaken Pharmaceutical Co., Ltd. provided Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026. For the period, the company expects net sales of JPY 88,000 million, operating profit of JPY 5,200 million and Profit attributable to owners of parent company of JPY 3,400 million or basic earnings per share of JPY 89.79.

On January 17, 2025, the company closed the transaction. The company amended the terms of the transaction. The company issued 1,791,400 common shares at issue price of ¥4,333 per share for gross proceeds of ¥7,762,136,200 in the transaction.

Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025

Kaken Pharmaceutical Co., Ltd., Board Meeting, May 30, 2025.

Kaken Pharmaceutical Co., Ltd. expected to report Q1 2026 results on August 1, 2025. This event was calculated by S&P Global (Created on May 27, 2025).

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.

Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for full year from April 1, 2025 to March 31, 2026. For the period, the company expects net sales of JPY 88,000 million, operating profit of JPY 5,200 million and Profit attributable to owners of parent company of JPY 3,400 million or basic earnings per share of JPY 88.53.

Kaken Pharmaceutical Co., Ltd. announced dividend of JPY 75.00 per share for fiscal year ended March 31, 2025 against JPY 75 per share a year ago, payable on June 30, 2025.

Kaken Pharmaceutical Co., Ltd. provided dividend guidance for second quarter of 2026 and fiscal year ending March 31, 2026. For the quarter, the company expects to pay a dividend of ¥95 per share against ¥75 per share a year ago. For the year, the company expects to pay a dividend of ¥95 per share against ¥75 per share a year ago.

From April 1, 2025 to April 14, 2025, the company has repurchased 538,800 shares, representing 1.42% for ¥2,340.6 million. With this, the company has completed the repurchase of 1,800,000 shares, representing 4.75% for ¥8,273.76 million under the buyback announced on February 26, 2025.

The company closed its plan on April 14, 2025.

Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.

From February 26, 2025 to March 31, 2025, the company has repurchased 1,261,200 shares, representing 3.33% for ¥5,933.15 million. With this, the company has completed the repurchase of 1,261,200 shares, representing 3.33% for ¥5,933.15 million under the buyback announced on February 26, 2025.

Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for approximately $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The acquisition includes FYARRO and associated infrastructure, including the majority of Aadi employees who support the FYARRO business. Upon closing of the transaction, Kaken will also acquire the rights to the Aadi name and trademark. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. For the period ended September 30, 2024, FYARRO has a cumulative revenue of $25.2 million. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the agreement. Completion of the deal is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing the consummation of the purchase, and the completion of certain internal pre-closing restructuring transaction. The transaction is expected to close in the first half of 2025. The net proceeds from the transaction are expected to fund operations into late-2028. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor and Nomura Securities Co., Ltd. acted as financial advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to Whitehawk Therapeutics, Inc and Leerink Partners LLC acted as financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for approximately $100 million on March 25, 2025. Upon the closing of the divestiture, Kaken Pharmaceutical paid a cash payment of $102.4 million, following applicable purchase price adjustments under the Purchase Agreement.

Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025

Alumis Inc. and Kaken Pharmaceutical Co. Ltd. announced that the companies have entered into a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases. Under the terms of the agreement, Alumis will receive $40 million in upfront and near-term co-development payments in 2025 to 2026, with the potential to earn up to approximately $140 million in additional payments based on the achievement of milestones, and field option payments. Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties on aggregate net sales of ESK-001 in Japan. Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 inJapan, and Alumis will retain rights to ESK-001 in all other geographies. Kaken will also contribute to a portion of the global development costs of ESK-001.

Kaken Pharmaceutical Co., Ltd. announced a private placement to issue 2,292,300 common shares at issue price of ¥4,333 per share for gross proceeds of ¥9,932,535,900 on December 26, 2024 . The transaction includes participation from new investor,Johnson & Johnson Innovation - JJDC, Inc. The transaction will happen through third party allocation. The issue date will be from January 15, 2025 to January 20, 2025. The transaction has been approved at board of director meeting of the company. The company will bear issuance sundry expenses of ¥12,500,000 and will receive net proceeds of ¥9,920,035,900. The investor acquire 5.69% stake in the company.

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.

The Board of Directors of Kaken Pharmaceutical Co., Ltd. has authorized a buyback plan on February 26, 2025.

Kaken Pharmaceutical Co., Ltd. provided dividend guidance of JPY 75.00 per share for the Year ending March 31, 2025 as compared to dividend of JPY 75.00 per share a year ago.

Kaken Pharmaceutical Co., Ltd. Presents at BIO Partnering @JPM Week, Jan-13-2025 . Venue: San Francisco Marriott Marquis, San Francisco, California, United States.

Kaken Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on January 13, 2025).

Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for approximately $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The acquisition includes FYARRO and associated infrastructure, including the majority of Aadi employees who support the FYARRO business. Upon closing of the transaction, Kaken will also acquire the rights to the Aadi name and trademark. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. For the period ended September 30, 2024, FYARRO has a cumulative revenue of $25.2 million. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the agreement. Completion of the deal is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing the consummation of the purchase, and the completion of certain internal pre-closing restructuring transaction. The transaction is expected to close in the first half of 2025. The net proceeds from the transaction are expected to fund operations into late-2028. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor and Nomura Securities Co., Ltd. acted as financial advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to Whitehawk Therapeutics, Inc and Leerink Partners LLC acted as financial advisor to Aadi Bioscience, Inc.

Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025

Kaken Pharmaceutical Co., Ltd., ¥ 75.0, Cash Dividend, Mar-28-2025

Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024